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Patient registries often lack indicators of the disease as 
experienced by patients, e.g. treatment satisfaction and 
self-assessed disease severity. There is scarce information 
about the relationship between these assessments and 
currently existing instruments used in treatment eva-
luation. Our objective was to explore the importance of 
these indicators among patients with psoriasis in Finland 
and Sweden, in relation to treatment patterns and cur-
rent measures of health-related quality of life. Data were 
collected from a patient survey and a retrospective chart 
review for 273 patients over 12 months. To assess psoria-
sis treatment completely, it is necessary to consider the 
impact of the disease on the patient in terms of treatment 
satisfaction, disease severity and health-related quality 
of life. The individual disease burden on patients should 
play a central role in formulating treatment goals. Clini-
cian- and patient-based perspectives of the overall im-
pact of psoriasis can assist clinical decision-making and 
evaluations of treatments. Key words: psoriasis; disease 
severity; patient satisfaction; HRQoL; patient registries.
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Psoriasis is a chronic, immune system-related dermato-
logical disease that causes inflammation and damages 
the involved tissues, including primarily the skin. In 
Sweden, an estimated 250,000 persons have psoriasis 
(1) and the corresponding figure for Finland is 150,000 
(nearly 3% of the populations in both countries) (2). Men 
and women are equally affected. Plaque psoriasis is the 
most common form and accounts for more than 80% 
of all cases (1). Approximately 5–20% of people with 
psoriasis also have joint inflammation called psoriatic 
arthritis, which causes pain, stiffness and restricted mo-
tion (1). In addition to these physical effects, psoriasis 
also has a significant impact on a patient’s health-related 
quality of life (HRQoL) (3, 4). Studies have shown that 
patients with psoriasis experience difficulties such as 
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maladaptive coping responses, problems in body image, 
self-esteem, and self-concept and often have feelings of 
stigma, shame and embarrassment regarding their ap-
pearance (5). Moreover, quality of life of partners and 
relatives of people with psoriasis can also be affected (6). 
A recent study reports that productivity loss in patients 
with psoriasis is related primarily to HRQoL and less to 
disease severity (7). 
Several new therapeutic options for psoriasis have 
been tested in clinical trials in recent years (8). New 
biological response modulators (BRMs) have been 
introduced. These new agents are relatively costly (9), 
but have been shown to have a great impact on symptom 
relief and HRQoL of a large share of patients who have 
received biologic treatment (10–12).
Currently, such patient registries as the database 
The Swedish Registry for Systemic Psoriasis Treat-
ment (PsoReg), which was created in 2007 in order to 
“analyse safety and effectiveness of different systemic 
psoriasis treatments” (13), lack information on self-
assessed disease severity and patients’ satisfaction 
with treatment. This is a problem for overall evaluation 
because patient perception of disease status, satisfaction 
with treatment, and disease burden are key indicators. 
We know from population-based studies that even 
patients with limited skin involvement are often dis-
satisfied with their treatment and find the disease highly 
problematic in everyday life (14, 15). 
The aims of this study were to explore the correlation 
between patient’s treatment satisfaction, quality of life, 
and self-assessed disease severity based on experience 
from Finnish and Swedish patients, and to determine 
whether these parameters should be included broadly 
in patient registries for patients with psoriasis. 
MATERIALS AND METHODS
The data material was based on a retrospective study of patients 
with psoriasis from two dermatology clinics in different parts 
of Sweden, and one clinic in Finland. The inclusion criteria 
were diagnosis of plaque psoriasis or both plaque psoriasis and 
psoriasis arthritis. The exclusion criterion was participation in 
a clinical trial at the time of the study. Because this was a non-
interventional study, no sample size calculation was performed 
and the planned number of subjects (150 patients from each 
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centre in Sweden and 150–200 patients in Finland) was chosen 
to represent a reasonable workload for the clinical investigators. 
Since data collection was retrospective and covered a treatment 
period of 12 months (from 1 September 2007 to 31 August 2008 
in Sweden, and from 15 January 2008 to 14 January 2009 in 
Finland), each patient had necessarily been diagnosed with 
psoriasis 12 months or more before inclusion in the study. Each 
participating centre investigated their local patient registers and 
included patients who met the inclusion criteria. Patients at the 
Swedish sites were consecutively included from 31 August 2007 
and backwards until the planned number of patients had been 
reached. The corresponding date in Finland was 31 December 
2007. In Sweden, 310 patients were included and in Finland 
193 patients. 
In Sweden, data were collected from three sources: a patient 
survey, a review of patient records during one year, and data 
from the drug register at the Centre for Epidemiology (EpC) 
at the National Board of Health and Welfare (NBHW, Social-
styrelsen). Data for Finland were collected from two sources: a 
patient survey and a review of patient records. A code register 
containing a patient serial number, name and person identifica-
tion number of patients included was generated at each clinic. 
The register was kept at the clinic, but the serial number was 
used to link data from the different sources. Permission to per-
form the study was obtained from ethics committees in Finland 
and Sweden and informed consent was received from patients 
to collect data from the different sources. 
Patient survey
A questionnaire including predefined response alternatives was 
posted to the patients. The questions concerned psoriasis treat-
ment, present health state, disease severity, level of satisfaction 
with current treatment, reasons for any dissatisfaction, and work 
status including absences from work and work impairment due 
to psoriasis. Specifically, patients were asked about number of 
absence days from work due to psoriasis during the last year 
(absenteeism) and to estimate how many days they had had pso-
riasis problems while still working and their working capacity 
as a percentage during these days (presenteeism). 
Treatment satisfaction was measured on a scale from zero, 
representing very dissatisfied, to ten, representing very satis-
fied. The patients were also asked to judge their current disease 
severity on five levels ranging from no problems to very severe 
problems. Present life quality was captured with the generic 
EuroQol instrument (EQ-5D), the EQ-5D Visual Analogue Scale 
(VAS), and the disease-specific instrument the Dermatology 
Life Quality Index (DLQI). 
The EQ-5D is a widely used, validated preference-based 
instrument designed to measure general health status. EQ-
5D could preferably be used together with a disease-specific 
questionnaire. The instrument is suggested for Quality Adjusted 
Life Years (QALY) weightings in health-economic evaluations 
by, for example, the Swedish reimbursement authority (16). It 
consists of five items to assess degree of physical functioning 
(mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression). Each question is divided into three levels: 
no problems, some problems, and severe problems. This allows 
243 (35) possible health states. A single numeric index (weight) 
of health status can then be generated from the five dimensions. 
The EQ-5D QALY weight associated with each individual health 
state was based on weights developed by Dolan et al. (17). 
The DLQI instrument contains ten items and the score ranges 
from 0 to 30. It was developed as a simple, compact, and prac-
tical questionnaire for use in dermatology clinical settings to 
assess limitations related to the impact of skin disease (18). The 
DLQI has well-established properties of reliability and validity 
in the dermatology setting (19, 20). It has been proposed that 
the score reflects the degree of impairment imposed by the skin 
disease on HRQoL (21). 
Review of patient records and access to drug register data
A review of patient records was conducted by a dermatologist 
from each centre for those patients who had responded to the 
survey. Information about drug prescriptions was collected in 
both countries. In Sweden, detailed data about prescriptions 
and dispatched drugs from pharmacies of a specified number 
of drugs used in psoriasis treatment were also collected from 
the national drug register at the Centre for Epidemiology for 
the 12-month period. We were unfortunately denied access to 
similar data from the Social Insurance Institution of Finland 
(KELA) drug register for Finland. 
Statistical analyses 
DLQI scores and EQ-5D weights were related to the treatment of 
the psoriasis disease and to disease severity. Correlations were 
performed to test for significant associations between variables. 
To test for a relationship between variables on an interval scale 
we have analysed the data using the Pearson’s correlation coef-
ficient. Spearman’s rank correlation was applied when one or 
both of the variables being analysed consisted of ranks, i.e. data 
on an ordinal scale. F-tests and t-tests were performed to test 
significant differences between groups of patients. All statistical 
tests were performed at the 0.05-level of significance and were 
two-sided unless otherwise specified. 
RESULTS
Patient characteristics
The response rate in Finland was 57%, as 110 of the 193 
patients responded. In Sweden, 163 patients responded 
out of 310, corresponding to a response rate of 53%. 
Most of the patients were between 50 and 65 years of 
age and the majority of the respondents were men (66% 
in Sweden and 59% in Finland). Plaque psoriasis was 
the most common diagnosis, and 17.6% in Finland and 
Table I. Baseline demographics and social characteristics
Patient characteristics
Swedish patients 
(n = 163)
Finnish patients 
(n = 110)
Male, n (%) 108 (66) 65 (59)
Mean age, years (min, max) 51 (22, 76) 53 (26, 75)
Median time since diagnosis, years 
(min, max)
14 (2, 71) 18 (2, 65) 
Plaque psoriasis, n (%) 145 (89.0) 89 (82.4)
Plaque psoriasis + psoriasis arthritis, 
n (%)
18 (11.0) 19 (17.6)
Other chronic disease, n (%)a 57 (35.0) 61 (55.5)
Malignant disease 5 (3.1) 4 (3.6)
Cardiovascular disease 22 (13.5) 42 (38.2)
Collagenosis or other joint disease 9 (5.5) 3 (2.7)
Asthma or chronic obstructive lung 
disease
8 (4.9) 6 (5.4)
Diabetes 9 (5.5) 11 (10.0)
kidney disease 1 (0.6) 0 (0)
Other chronic disease 30 (18.4) 50 (45.4)
Full-time employed, n (%) 82 (50.3) 58 (53.6)
Part-time employed, n (%) 12 (7.4) 8 (7.3)
aSeveral of the patients had more than one chronic disease.
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11% in Sweden had been diagnosed with both plaque 
psoriasis and psoriasis arthritis. Moreover, 55.5% of 
Finnish patients and 35% of Swedish patients were 
diagnosed with another chronic disease (Table I).
It is common that patients with psoriasis use multiple 
drug treatments concurrently, i.e. both local, systemic 
and biological treatment. Therefore, we divided the 
patients hierarchically into six different treatment 
groups depending on the most potent medication the 
patient had used during the last 12 months, as shown 
in Table II. 
Emollients and topical corticosteroids alone were 
used by 164 of the patients (64% in Sweden and 54% 
in Finland) during the study period, while 72 patients 
(21% in Sweden and 34% in Finland) had used systemic 
treatment (not biological). In total, 37 patients (15% 
in Sweden and 12% in Finland) had used biological 
treatment during part of or during the whole 12-month 
period. Fourteen patients (6% in Sweden and 4% in 
Finland) had used biological treatment during the whole 
time-period. 
Treatment patterns, treatment satisfaction and quality of life
The question on self-assessed disease severity revealed 
that the majority of patients on Systemic and biological 
(mix) and Biological 12 months treatment experienced 
their disease as mild at the time of the survey, as il-
lustrated in Fig. 1. None of the patients, on biological 
treatment, experienced the disease as severe. However, 
17% of the patients in the Systemic and biological 
group and 20% of the patients in the Systemic (not 
biological) group reported severe problems. 
Fig. 1 also shows the degree of satisfaction with cur-
rent treatment. We find a significant difference between 
the treatment groups regarding treatment satisfaction 
(p ≤ 0.000). Patients in the Emollients group are least 
satisfied and patients in the Biological treatment < 12 
months and Biological 12 months groups are most sa-
tisfied with their current treatment. Patients on Systemic 
(not biological) are less satisfied with their treatment 
compared with patients who have received biological 
treatment only for 12 months or less (p ≤ 0.001). The 
Table II. Definition of treatment groups
Type of treatment
Swedish
patients, n (%)
Finnish
patients, n (%) 
Emollients only 38 (23.3) 11 (10.0)
Topical corticosteroids: Patients who have used topical corticosteroids during part of or during the entire examined 
time period. Patients can also have used emollients.
66 (40.5) 49 (44.5)
Systemic (not biological): Patients who have used systemic treatment but not biological agents during part of or 
during the entire time perioda. 
34 (20.9) 38 (34.5)
Systemic and biological (mix): Patients who have used both systemic treatment and biological treatment at any time 
during the 12 months. Patients have used biological treatment less than 12 monthsa.
6 (3.7) 6 (5.5)
Biological <12 months: Patients who have used biological treatment less than 12 months during the examined time 
period. None of these patients have used other systemic treatment during the time perioda.
9 (5.5) 2 (1.8)
Biological 12 months: Patients who have used biological treatment during the whole examined time perioda,b. 10 (6.1) 4 (3.6)
Total 163 (100.0) 110 (100.0)
aPatients can also have used emollients and/or topical corticosteroids; bPatients can also have used other systemic treatment.
Fig. 1. Distribution of self-assessed 
disease severity (mild, moderate or 
severe), and degree of satisfaction 
with treatment (0 = very dissatisfied, 
10  = very satisfied) per treatment 
group, n  =  271 (2 missing).
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patients estimated their average output capacity at work/
studies (work productivity) during their last psoriasis 
outbreak to 82.1% (SD 1.6), but no significant difference 
can be detected by the treatment group. Patients also 
responded to what type of problem they were expe-
riencing with their current treatment. The most common 
problems were limited effects from treatment, sticky 
cream, and that the treatment was time consuming. 
On average, the patients’ QoL measured by EQ-5D 
was quite high, mean QALY weight 0.75 (SD 0.23). 
The mean DLQI score was 6.8 (SD 6.1), which cor-
responds to a moderate effect on the patient’s life. As 
illustrated in Fig. 2, the groups Topical corticosteroids, 
Biological <12 months and Biological 12 months all had 
an EQ-5D score above the mean, while the DLQI score 
varied between 6.3 (moderate effect on patient’s life) 
and 4.1 (small effect on patient’s life) for these patient 
groups. The lowest EQ-5D score (indicating the lowest 
QoL) was reported by patients in the group Systemic 
and Biological <12 months, and this group also had the 
highest DLQI, 8.8 (moderate effect on patient’s life). 
However, no statistically significant differences for 
QoL measured by EQ-5D and DLQI could be detected 
between the treatment groups. 
Table III shows the correlations between the HRQoL 
measures, patient treatment satisfaction, self-assessed 
disease severity and work productivity. We find that 
patients having higher discomfort and a larger effect 
on their lives according to DLQI have lower QoL ac-
cording to EQ-5D. We note that the DLQI score is more 
highly correlated with self-assessed disease severity 
than with the EQ-5D. The correlations with treatment 
satisfaction show that patients who are less satisfied 
with their treatment also have more severe disease and 
a lower HRQoL according to EQ-5D and DLQI. We find 
that work productivity is more correlated with HRQoL 
than with self-assessed disease severity.
DISCUSSION
The present study is based on a patient sample of 273 
patients with psoriasis being treated in Finland and 
Sweden. Our results reveal differences in self-assessed 
disease severity, treatment satisfaction and HRQoL 
depending on which type of treatment the patient has re-
ceived. We observe that patients treated with biological 
agents seem to have higher QoL compared with other 
patients. Most of the patients in this treatment group 
also state that they experience “no problem” or “mild 
problem” with their illness. In addition, these patients 
are more satisfied with their treatment compared with 
the other groups.
We lacked information from any patient registry in 
Finland, but in Sweden there is a database PsoReg, 
containing information about more than 800 patients 
on systemic treatment (including biological treatment) 
from all over Sweden (22). In comparison with the data 
published from PsoReg, we find several similarities. 
The age distribution is similar to our study, with most 
patients between 40 and 65 years of age (22). Further-
more, just as in PsoReg, men were overrepresented in 
our study population (63% vs. 60% in PsoReg) (22). 
Similar overrepresentation of male patients in Swedish 
dermatology centres has been noted in other studies (23, 
24). In PsoReg, the mean EQ-5D score for patients at 
inclusion was 0.75 (SD 0.23) and the DLQI score was 
7.44 (SD 7.2) (22). In our study, the mean EQ-5D score 
for the whole patient population was 0.75 (SD 0.23) and 
the DLQI score was 6.8 (SD 6.1). However, our patient 
sample also includes patients that have been treated with 
Table III. Correlationsa among patient-related outcome measures, n = 273
Measure DLQI EQ-5D EQ-5D VAS
Patient treatment 
satisfaction
Self-assessed 
disease severity
Productivity at 
work
DLQI 1.0
EQ-5D –0.5234 1.0
EQ-5D VAS –0.5008 0.5738 1.0
Patient treatment satisfaction –0.4175 0.2807 0.3758 1.0
Self-assessed disease severity 0.7067 –0.4900 –0.4331 –0.5367 1.0
Productivity at work –0.4735 0.4126 0.3892 0.0695, ns –0.1689* 1.0
aAll correlations were significant at p ≤ 0.000, unless otherwise noted. 
*p ≤ 0.05. 
ns: non-significant; DLQI: Dermatology Life Quality Index, EQ-5D: EuroQol; VAS: visual analogue scale.
Fig. 2. Quality of life: Mean EuroQol (EQ-5D) and Dermatology Life 
Quality Index (DLQI) as reported by patients in Finland and Sweden, n = 266 
(7 missing).
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only topical therapy during the observational period, 
while PsoReg is limited to patients treated with systemic 
drugs. A substantial number of patients had both psoria-
sis and other chronic diseases. This could, of course, also 
have had an influence on the patient’s well-being. 
A German study concluded that patients who cannot 
adequately be managed with standard treatments have 
high disease activity and a lower HRQoL (25). We find 
that patients on systemic treatment (not biological) are 
less satisfied with their treatment compared with patients 
who have received biological treatment. It is therefore 
possible that these patients are treated sub-optimally. 
The results from the present study indicate that there 
are still potential health gains to be made through initia-
tion of new more effective treatments for some patients 
treated with systemic drugs.
One limitation of the present study is the small 
number of patients and especially the small number 
of patients on systemic treatment. A second limitation 
of the study is that the patients were collected from 
specialized clinics at university hospitals; as such, the 
study population may be unrepresentative. Typically, 
patients with moderate and severe psoriasis problems 
are treated in dermatological clinics in Finland and 
Sweden. The number of patients with severe psoriasis 
who were treated with systemic agents, and especially 
biologic drugs, was relatively low, perhaps because of 
the exclusion of patients participating in a clinical trial 
at the time of the present study. There might therefore 
be a selection bias due to the exclusion criteria caus-
ing fewer patients with severe psoriasis and thus less 
patients on systemic drugs. 
Our study reveals the importance of considering self-
assessed disease severity, treatment satisfaction, and 
HRQoL. It is evident from this survey that patients with 
psoriasis, who experience limitations in their HRQoL, 
experience their disease as severe and are dissatisfied 
with their treatment. Moreover, we can conclude that 
treatment satisfaction varies between treatment groups. 
Patients on biological treatment during the whole study 
period seem to be most satisfied with their treatment. 
Some of the patients treated with systemic agents other 
than biological might benefit from a more optimal 
psoriasis treatment, as some are dissatisfied with their 
treatment. One possible explanation can be that the 
conventional traditional and new treatment options are 
not being used consistently (26). Patients can easily be 
followed up in a patient register and with more infor-
mation available about their disease a more optimal 
treatment can be chosen. Moreover, patient registers 
should include all patients with psoriasis and not only 
those on systemic treatment. Patients with self-assessed 
severe disease would particularly benefit from patient 
registers adding more information, as a more optimal 
treatment for these patients would mean large positive 
effects on their overall QoL. 
The findings of the present study imply that it may be 
insufficient to ask patients about treatment satisfaction. 
It is also important to ask about work productivity. As 
shown in a previous German study, the correlation 
between HRQoL and work productivity in the present 
study is higher than between work productivity and 
disease severity (7).
The relatively high correlation between DLQI and 
self-assessed disease severity in the present study 
indicates that this way of assessing the patient’s con-
dition could be used to evaluate symptoms and effects 
of treatments. Currently, treatment satisfaction is often 
used as a treatment goal in the Nordic countries, but our 
study shows a relatively low correlation between treat-
ment satisfaction and HRQoL measures and between 
treatment satisfaction and self-assessed disease severity. 
This could mean that those pursuing this traditional 
treatment goal may be over-treating some patients, and 
under-treating others. The individual disease burden 
on the patient should play a central role in formulating 
treatment goals.
For a complete assessment of psoriasis treatment, it 
is necessary to provide evidence of the impact of the 
disease on the patient in terms of treatment satisfaction, 
disease severity, and HRQoL. A large European study 
on 18,000 patients with psoriasis also concluded the 
importance of these measures (15). Users of patient 
registers will benefit if the registers include this in-
formation, since the patients’ views are of great value 
to anyone interested in improving the treatment and 
management of psoriasis. Clinician- and patient-based 
perspectives of the overall impact of psoriasis can assist 
clinical decision-making and evaluations of appropriate 
treatments. 
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